Alyeska Investment Group’s Pacira BioSciences PCRX Stock Holding History

Alyeska Investment Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200,846	Closed	-$4.8M	–	687
2025 Q2	$4.8M	Sell	200,846 -1,107,240	-85%	-$27.9M	0.02%	429
2025 Q1	$32.5M	Buy	+1,308,086	New	+$31.3M	0.13%	192
2018 Q2	–	Sell	-648,920	Closed	-$20.2M	–	506
2018 Q1	$20.2M	Sell	648,920 -371,416	-36%	-$13.2M	0.17%	154
2017 Q4	$46.6M	Buy	1,020,336 +381,393	+60%	+$15.1M	0.37%	91
2017 Q3	$24M	Sell	638,943 -322,680	-34%	-$13M	0.18%	164
2017 Q2	$45.9M	Sell	961,623 -451,570	-32%	-$21M	0.38%	95
2017 Q1	$64.4M	Buy	1,413,193 +870,083	+160%	+$37.6M	0.52%	56
2016 Q4	$17.5M	Buy	543,110 +501,374	+1,201%	+$16.7M	0.15%	222
2016 Q3	$1.43M	Buy	+41,736	New	+$1.64M	0.01%	401

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's PCRX Position: Q3 2025 in Review

Alyeska Investment Group sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 200,846 shares — an estimated $4.8M sold.

Alyeska Investment Group first reported a position in PCRX in Q3 2016 and held it in 9 quarters. The position peaked at $64.4M in Q1 2017. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

Alyeska Investment Group reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
Alyeska Investment Group sold 200,846 Pacira BioSciences shares in Q3 2025, an estimated $4.8M.
Alyeska Investment Group first reported a position in Pacira BioSciences in Q3 2016 and held it in 9 quarters.
Alyeska Investment Group's Pacira BioSciences position peaked at $64.4M in Q1 2017.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.